TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16075824

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Northern Americas (NA)
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Caribbean (CA)
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in Eurasia (EA)
Number of subjects: 22576

Group type: COMPARATOR
Intervention: All-cause mortality, fatal or nonfatal MI, fatal or nonfatal stroke, newly diagnosed diabetes in Northern Americas (NA)
Number of subjects: 22576
Study: 12436031

Group type: EXPERIMENTAL
Intervention: Prophylactic barbiturate therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective head cooling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic mild hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate and calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study: 9935200

Group type: EXPERIMENTAL
Intervention: INK4A deletion (4/55 cases)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: CDK4 gene amplification (6/67 samples)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined alterations (INK4A and CDK4)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Genetic lesions deregulating the G1 to S cell cycle checkpoint
Number of subjects: 79
Study: 8520164

Group type: EXPERIMENTAL
Intervention: CAF + MPA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MPA alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MPA and CAF + MPA
Number of subjects: 64
Study: 2106545

Group type: EXPERIMENTAL
Intervention: Daily infusions of 200 cc of a 20% lipid emulsion with TPN for the first week, followed by daily intravenous lipid for the next 3 weeks (0.7 g lipid/kg BW/day and approximately 280 mg of choline/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: TPN without lipid for the first week, followed by daily intravenous lipid for the next 3 weeks
Number of subjects: 25
Study: 31471494

Group type: EXPERIMENTAL
Intervention: Subcutaneous needle drainage
Number of subjects: 31
Study: 31753198

Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD)
Number of subjects: 79
Study: 29788133

Group type: EXPERIMENTAL
Intervention: Group Music and Imagery (GrpMI) intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no additional service)
Number of subjects: 56
Study: 27143873

Group type: EXPERIMENTAL
Intervention: Lysozyme (270 mg) administered orally for 52 weeks as an add-on to standard therapies
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo administered orally for 52 weeks as an add-on to standard therapies
Number of subjects: 408
Study: 24529135

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 830
Study: 22194217

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a
Number of subjects: 103
Study: 19963442

Group type: EXPERIMENTAL
Intervention: Insulin-resistant subjects with impaired fasting glycaemia (IFG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insulin-resistant subjects with normal glucose regulation (NGR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) subjects
Number of subjects: 90
Study: 17957417

Group type: EXPERIMENTAL
Intervention: Remote Simultaneous Medical Interpreting (RSMI)
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Usual and Customary (U&C)
Number of subjects: 1276
Study: 15721501

Group type: EXPERIMENTAL
Intervention: Egg ingestion (2 eggs daily for 6 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oat ingestion (oats daily for 6 weeks)
Number of subjects: 49
Study: 11993588

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cancer screening
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: General lifestyle advice
Number of subjects: 1000
Study: 9445307

Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled corticosteroid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7611203

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (524 mg q.i.d.) and metronidazole (250 mg q.i.d. for the first 2 weeks) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (uninfected patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term follow-up (mean, 34 months)
Number of subjects: 100
Study: 2121552

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gonadotropins alone
Number of subjects: 48
Study: 628361

Group type: EXPERIMENTAL
Intervention: 2 g probenecid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100 mg/day benzbromaron
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 300 mg/day benzbromaron
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2 g/day probenecid
Number of subjects: 39
Study: 30635187

Group type: EXPERIMENTAL
Intervention: Trifecta biological valve
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mosaic Ultra biological valve
Number of subjects: 90
Study: 27914318

Group type: EXPERIMENTAL
Intervention: Stressor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 60
Study: 25844569

Group type: EXPERIMENTAL
Intervention: Genetic testing for type 2 diabetes risk
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Belief in genetic causality
Number of subjects: 409
Study: 22314758

Group type: EXPERIMENTAL
Intervention: Specific information about games using the interactive software 'Amazing Chateau'
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Rational emotive education (REE)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 21552190

Group type: EXPERIMENTAL
Intervention: Computer monitor viewed through goggles providing 40 lux of short-wavelength (blue) light
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Computer monitor only
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dark control (orange-tinted safety glasses)
Number of subjects: 21
Study: 18445058

Group type: EXPERIMENTAL
Intervention: Normal saline (N/S) infusion at a rate of 800 ml/hour during DSE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dobutamine alone
Number of subjects: 100
Study: 15943850

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg bd
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg daily
Number of subjects: 13
Study: 12434937

Group type: EXPERIMENTAL
Intervention: Home-based, moderate intensity exercise program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 96
Study: 10217000

Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of prothrombin fragment 1 + 2 (F1 + 2)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of thrombin-antithrombin III complexes (TAT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Preoperative plasma levels of D-dimer
Number of subjects: 159
Study: 7564481

Group type: EXPERIMENTAL
Intervention: 15 mg of oral methotrexate weekly
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study: 1941668

Group type: EXPERIMENTAL
Intervention: Occlusal Indicator Wax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accufilm
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-Scan system
Number of subjects: 0
Study: 7006657

Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: morphine 10 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: dezocine 5 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: dezocine (all doses)
Number of subjects: 160
Study: 30146654

Group type: EXPERIMENTAL
Intervention: Micro-lecture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 20
Study: 28770268

Group type: EXPERIMENTAL
Intervention: Strong anchoring with large activity in contractile droplets (planar anchoring)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strong anchoring with large activity in extensile droplets (normal anchoring)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tuning activity and anchoring strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous rotations under strong anchoring
Number of subjects: 0
Study: 25622538

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 1.2 g
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 2.4 g
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 4.8 g
Number of subjects: 48

Group type: COMPARATOR
Intervention: Guanidinoacetic acid (GAA)
Number of subjects: 48
Study: 24171842

Group type: EXPERIMENTAL
Intervention: Football Fans in Training (FFIT) programme for 12 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waitlist comparison group (received FFIT after four months)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity and diet improvements
Number of subjects: 103
Study: 21183154

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis based on Nugent score ≥7
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis based on vaginal fluid pH ≥5
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Nugent score and vaginal fluid pH
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Adjustment for relevant covariates
Number of subjects: 949
Study: 18838053

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg/day for one year
Number of subjects: 865
Study: 16026869

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day, 300 mg loading dose within 24 h prior to hospital admission) plus standard therapy (including ASA, 75‐325 mg/day) for 1 year
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard therapy alone (including ASA, 75‐325 mg/day) for life
Number of subjects: 1000
Study: 15556258

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU=540 mg vitamin E emulsion)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11230896

Group type: EXPERIMENTAL
Intervention: Washing with water and soap
Number of subjects: 99

Group type: COMPARATOR
Intervention: No washing
Number of subjects: 99
Study: 9260005

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 51
Study: 8234958

Group type: EXPERIMENTAL
Intervention: Interaction training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 28
Study: 2894219

Group type: EXPERIMENTAL
Intervention: Dipipanone 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 and 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30068393

Group type: EXPERIMENTAL
Intervention: Web-based platform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based platform plus online dietician assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist with minimal intervention
Number of subjects: 0
Study: 27765010

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (Granisetron)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 65
Study: 25100106

Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone (Prolutex) 25 mg daily
Number of subjects: 800

Group type: COMPARATOR
Intervention: Vaginal progesterone (Endometrin) 100 mg bid daily
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone (Prolutex)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Vaginal progesterone (Endometrin)
Number of subjects: 800
Study: 22497752

Group type: EXPERIMENTAL
Intervention: Aclidinium 100 μg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 20430356

Group type: EXPERIMENTAL
Intervention: Interactive computer trainer
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 43
Study: 18281658

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg orally daily until progression
Number of subjects: 103

Group type: COMPARATOR
Intervention: Carboplatin (AUC 6) and paclitaxel (200 mg/m² day 1 every 3 weeks) for up to four cycles
Number of subjects: 103
Study: 15969834

Group type: EXPERIMENTAL
Intervention: Traditional vigilance task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified vigilance task
Number of subjects: 0
Study: 14550317

Group type: EXPERIMENTAL
Intervention: Normal Food Intake (NFI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Food Restriction (RFI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control slides
Number of subjects: 16
Study: 10942632

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (9.5 microg/kg/day) for 9 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8630191

Group type: EXPERIMENTAL
Intervention: Intensive outpatient therapy (1 hr each of physical and occupational therapy, four times per week, for 12 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no treatment supplied)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 49
Study: 8400928

Group type: EXPERIMENTAL
Intervention: levodopa/dopa decarboxylase inhibitor alone (arm 1)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: levodopa/decarboxylase inhibitor/selegiline in combination (arm 2)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: bromocriptine (arm 3)
Number of subjects: 782
Study: 3553802

Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^7 bacilli)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (5 x 10^7 bacilli)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^8 bacilli)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (5 x 10^8 bacilli)
Number of subjects: 4
Study: 29306882

Group type: EXPERIMENTAL
Intervention: Thermal Imaging (TI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 47
Study: 27536869

Group type: EXPERIMENTAL
Intervention: Dietary protein at 10%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dietary protein at 15%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dietary protein at 25%
Number of subjects: 22
Study: 23200175

Group type: EXPERIMENTAL
Intervention: Selumetinib plus docetaxel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 87
Study: 21391924

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - 100 mg/kg bolus IV over 15 min, followed by 40 mg/kg/day IV infusion for 24 h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study: 19364873

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) single-dose treatment
Number of subjects: 89
Study: 17572835

Group type: EXPERIMENTAL
Intervention: Low-intensity back-strengthening exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 80
Study: 15084901

Group type: EXPERIMENTAL
Intervention: Nefazodone (200-600 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11532112

Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 166

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 166
Study: 9771299

Group type: EXPERIMENTAL
Intervention: 20 ml kg‐1 of crystalloid fluid preload over 20 min
Number of subjects: 58

Group type: COMPARATOR
Intervention: No fluids before induction of anaesthesia
Number of subjects: 58
Study: 7830390

Group type: EXPERIMENTAL
Intervention: Carbohydrate maltodextrin supplement (MD; 5% maltodextrin + 2% fructose) at dosage of 0.25 g.kg‐1 body weight (mean intake rate, total: 37 g.h‐1, 148 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-caloric placebo (PL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbohydrate maltodextrin supplement (MD)
Number of subjects: 14
Study: 3071596

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril 100 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30827971

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, church-based health-promotion intervention over six weeks.
Number of subjects: 321

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 321
Study: 27933698

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 16 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 24 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin therapy
Number of subjects: 117
Study: 25938158

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine at a dose of 0.2 μg/kg.h for 12 hours
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intravenous normal saline for 12 hours
Number of subjects: 156
Study: 23362991

Group type: EXPERIMENTAL
Intervention: Specific psychological intervention (6 sessions) along with fluoxetine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-specific psychological intervention (6 sessions) along with fluoxetine
Number of subjects: 15
Study: 21979458

Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 78
Study: 18778179

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) for 16 weeks
Number of subjects: 66
Study: 21809720

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:80 000 adrenaline
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2% lignocaine without vasoconstrictor (plain lignocaine)
Number of subjects: 33
Study: 16138713

Group type: EXPERIMENTAL
Intervention: Slow-release fluvastatin 80 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Immediate-release fluvastatin 40 mg/day
Number of subjects: 61
Study: 11876598

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (budesonide aqueous nasal spray: 128 microg b.i.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other scoring system
Number of subjects: 100
Study: 10322793

Group type: EXPERIMENTAL
Intervention: Differential DNA fragments isolated from cancerous tissues using arbitrary primer polymerase chain reaction (AP‐PCR).
Number of subjects: 12

Group type: COMPARATOR
Intervention: Southern blot analysis of genomic DNA from cancerous and non-cancerous tissues.
Number of subjects: 12
Study: 7649341

Group type: EXPERIMENTAL
Intervention: 1 mg/kg dropropizine orally, three times daily for 3 days
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 2 mg/kg levodropropizine orally, three times daily for 3 days
Number of subjects: 258
Study: 2668428

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once a day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Cefotaxime 2 g every 4 h
Number of subjects: 171
Study: 322677

Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchospasmin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29724729

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 115

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 115
Study: 27886078

Group type: EXPERIMENTAL
Intervention: 500 µg vitamin B12 and 400 µg folic acid daily
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919
Study: 24679384

Group type: EXPERIMENTAL
Intervention: Suicide Cognitions Scale (SCS)
Number of subjects: 326
Study: 22314083

Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplement (1000 IU cholecalciferol/day)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 20538094

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 100
Study: 18785056

Group type: EXPERIMENTAL
Intervention: Providing information about mnemonic features before the test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calling attention to features in test instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asking participants to rate their phenomenal experience
Number of subjects: 0
Study: 15867125

Group type: COMPARATOR
Intervention: 1 throat swab
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: 2 throat swabs
Number of subjects: 363
Study: 12803583

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP, 15 mg kg‐1, n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (TM, 10 mg kg‐1, n = 12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PL, NaCl, n = 12)
Number of subjects: 36
Study: 10372428

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg.kg‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8706483

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1752851

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25‐50 mg (N = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (N = 12)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intramuscular route of administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral route of administration
Number of subjects: 21